Charles River Laboratories
CRL
492 hedge funds and large institutions have $10.5B invested in Charles River Laboratories in 2020 Q3 according to their latest regulatory filings, with 74 funds opening new positions, 138 increasing their positions, 206 reducing their positions, and 45 closing their positions.
64% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 45
64% more call options, than puts
Call options by funds: $115M | Put options by funds: $70.3M
31% more funds holding in top 10
Funds holding in top 10: 13 → 17 (+4)
29% more capital invested
Capital invested by funds: $8.14B → $10.5B (+$2.37B)
6% more funds holding
Funds holding: 466 → 492 (+26)
0.24% less ownership
Funds ownership: 94.38% → 94.14% (-0.24%)
33% less repeat investments, than reductions
Existing positions increased: 138 | Existing positions reduced: 206
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$150M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$104M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$93M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$85M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$41.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$65.8M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$65.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$43.4M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$38.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$33.8M |
CRL Hedge Fund Activity: Q3 2020 in Review
492 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q3 2020, worth a combined $10.5B — up 29% from $8.14B a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new CRL positions and 45 closed out — a net gain of 29 holders — while 138 added to existing stakes and 206 trimmed.
The largest buyer was Marshall Wace, adding an estimated $150M. The largest seller was Renaissance Technologies, cutting an estimated $65.8M.
- 492 institutional investors held Charles River Laboratories (CRL) as of Q3 2020, up from 466 in Q2 2020.
- Funds reported $10.5B of Charles River Laboratories stock for Q3 2020, up 29% quarter-over-quarter.
- 74 funds opened new Charles River Laboratories positions in Q3 2020 and 45 closed out, a net change of +29 holders.
- The largest Charles River Laboratories buyer in Q3 2020 was Marshall Wace, an estimated $150M added.
- The largest Charles River Laboratories seller in Q3 2020 was Renaissance Technologies, an estimated $65.8M sold.
Based on aggregated 13F filings for Q3 2020.